Literature DB >> 10357395

High plasma levels of nelfinavir and efavirenz in two HIV-positive patients with hepatic disease.

R Maserati, P Villani, E Seminari, A Pan, S Lo Caputo, M B Regazzi.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10357395     DOI: 10.1097/00002030-199905070-00025

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


× No keyword cloud information.
  5 in total

1.  Single and multiple dose pharmacokinetics of nelfinavir and CYP2C19 activity in human immunodeficiency virus-infected patients with chronic liver disease.

Authors:  Y Khaliq; K Gallicano; I Seguin; K Fyke; G Carignan; D Bulman; A Badley; D W Cameron
Journal:  Br J Clin Pharmacol       Date:  2000-08       Impact factor: 4.335

2.  Pharmacokinetics of efavirenz (EFV) alone and in combination therapy with nelfinavir (NFV) in HIV-1 infected patients.

Authors:  P Villani; M B Regazzi; F Castelli; P Viale; C Torti; E Seminari; R Maserati
Journal:  Br J Clin Pharmacol       Date:  1999-11       Impact factor: 4.335

Review 3.  Efavirenz and nevirapine in HIV-1 infection : is there a role for clinical pharmacokinetic monitoring?

Authors:  Karen Dahri; Mary H H Ensom
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

Review 4.  Therapeutic drug monitoring: an aid to optimising response to antiretroviral drugs?

Authors:  Rob E Aarnoutse; Jonathan M Schapiro; Charles A B Boucher; Yechiel A Hekster; David M Burger
Journal:  Drugs       Date:  2003       Impact factor: 9.546

5.  Efavirenz concentrations in HIV-infected patients with and without viral hepatitis.

Authors:  Sofia A Pereira; Umbelina Caixas; Teresa Branco; Isabel Germano; Fátima Lampreia; Ana L Papoila; Emília C Monteiro
Journal:  Br J Clin Pharmacol       Date:  2008-06-09       Impact factor: 4.335

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.